Internazionale

Cina

Francia

Russia

Indonesia

Turchia

India

Vietnam

Spagna

Brasile e Portogallo

Privacy Policy

Terms & Conditions

Lobby

I giochi più popolari

Casinò dal vivo

Novità

Giochi Crash

Giochi da tavolo

Giochi di slot

Acquisto di bonus

Roulette

Fornitori

Tutte le promozioni

Bonus di benvenuto per le scommesse sportive

Bonus di benvenuto del casinò

Cashback settimanale

Club sportivo

Club VIP

Programma di affiliazione

Eventi in diretta

Sport

Esport

Tornei

Calcio

Pallacanestro

Tennis

Cricket

accademia

CENTRO ASSISTENZA

documentazione

Scommesse con criptovalute

Profilo

Le mie scommesse

I miei bonus

Impostazioni

Pool

Classifica

Pronostici

Informazioni su

token

Opportunità di lavoro

Contattateci

Risorse del marchio

Merch

Aggiungere monete e rete

Gioco responsabile

OG.Dexsport

Di tendenza al momento

Casinò

Home

This market will resolve to "Yes" if a natural meteoroid (bolide) explodes in Earth's atmosphere with a total impact energy greater than or equal to 1 megaton (1000 kilotons) of TNT equivalent between January 1 and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.

The object must be classified as a natural meteoroid; events involving artificial objects or reentry vehicles do not qualify.

The primary resolution source will be the NASA JPL Fireball and Bolide Data repository: https://cneos.jpl.nasa.gov/fireballs/. The relevant field for determining impact energy is the “Impact Energy (kt)” column. If this dataset has not been updated to include all relevant dates by February 28, 2027, or if the NASA JPL Fireball and Bolide Data repository becomes permanently unavailable, this market may resolve based on a consensus of credible sources including the European Space Agency (ESA), the International Asteroid Warning Network (IAWN), the U.S. Department of Defense, or credible reporting of a scientific consensus, such as a NASA press release.

1 megaton meteor strike in 2026?

Meteorite da 1 megatone nel 2026?

This market will resolve to "Yes" if Microsoft officially releases Project Helix by the listed date, 11:59 PM ET. Otherwise, this market will resolve to "No".

A qualifying product must be acknowledged to be part of Project Helix and be recognized as a major Xbox console, similar to the Xbox Series X or Xbox One. A new Xbox console not acknowledged by Microsoft as being part of Project Helix will not qualify.

In order to be considered released, the product must be available for purchase by the general public within the specified timeframe. An announcement or unveiling alone is not sufficient.

The primary resolution source for this market will be official statements from Microsoft. However, a consensus of credible reporting may also be used.

December 31, 2026

May 31, 2027

When will Project Helix be released?

Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

FDA approves Retatrutide this year?

La FDA approva la Retatrutide quest' anno?

This market will resolve to the third-largest company in the world by market cap on August 31, 2026, as of market close.

The resolution source for this market will be a consensus of credible reporting.

3° azienda più grande alla fine di agosto?

Panoramica del mercato

Di tendenza

Cronologia

Attività

Di tendenza

piattaforma

Scommesse sportive

Casinò

Promozioni

risorse

Servizi